Características Sociodemográficas e Medidas de Saúde Mental em Usuários de Cogumelos Psicoativos
DOI:
https://doi.org/10.34019/1982-1247.2026.v20.43945Palabras clave:
Psilocybe Cubensis, Depressão, Ansiedade, Estresse, DemografiaResumen
Em um contexto de uso difundido de cogumelos psicoativos, o objetivo deste estudo foi descrever características sociodemográficas e medidas de saúde mental em uma amostra não probabilística de usuários de cogumelos psicoativos no Brasil. A coleta on-line incluiu um questionário sociodemográfico e a Escala de Depressão, Ansiedade e Estresse (DASS-21). A amostra foi composta por 246 participantes, idade média de 29,5 anos (DP = 8,56), 54,1% homens, 83,7% com ensino superior ou mais e de todas as regiões do país apresentou maior prevalência de sintomatologia “Normal/Leve” para as três condições avaliadas, com uma parcela reduzida apresentando sintomas mais graves.
Descargas
Citas
Amorim, E. G. M., & Santos, D. A. R. (2022). O aumento do consumo de álcool e outras drogas durante a pandemia da covid-19 e seus principais impactos na saúde mental de jovens e adultos. Moitará - Revista do Serviço Social da UNIGRANRIO, 1(7), 101–114. Recuperado de https://publicacoes.unigranrio.edu.br/mrss/article/view/7348
Bastos, F. I. P. M., Vasconcellos, M. T. L., Boni, R. B., Reis, N. B., & Coutinho, C. F. S. (2017). III Levantamento Nacional sobre o uso de drogas pela população brasileira. ICICT/FRIOCRUZ. https://www.arca.fiocruz.br/handle/icict/34614
Bienemann, B., Ruschel, N. S., Campos, M. L., Negreiros, M. A., & Mograbi, D. C. (2020). Self-reported negative outcomes of psilocybin users: A quantitative textual analysis. PloS One, 15(2), e0229067. https://doi.org/10.1371/journal.pone.0229067
Biernacki, P., & Waldorf, D. (1981). Snowball sampling: Problems and techniques of chain referral sampling. Sociological Methods & Research, 10(2), 141–163. https://doi.org/10.1177/004912418101000205
Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., Rotrosen, J., Tonigan, J. S., & Worth, L. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 79(10), 953–962. https://doi.org/10.1001/jamapsychiatry.2022.2096
Borkel, L. F., Rojas-Hernández, J., Henríquez-Hernández, L. A., Santana Del Pino, Á., & Quintana-Hernández, D. J. (2024). Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: A correlational study. Expert Review of Clinical Pharmacology, 17(2), 165–176. https://doi.org/10.1080/17512433.2023.2295997
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology, 235(2), 399–408. https://doi.org/10.1007/s00213-017-4771-x
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3(7), 619–627. https://doi.org/10.1016/S2215-0366(16)30065-7
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., Leech, R., Curran, H. V., & Nutt, D. J. (2017). Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms. Scientific Reports, 7(13187). https://doi.org/10.1038/s41598-017-13282-7
Daldegan-Bueno, D., Révész, D., Morais, P. R., Barbosa, P. C. R., & Maia, L. O. (2022). Psychosocial and drug use assessment of regular vs. non-regular ayahuasca users in a Brazilian sample: A web-based survey. Substance Use & Misuse, 57(7), 1072–1081. https://doi.org/10.1080/10826084.2022.2063896
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5). https://doi.org/10.1001/jamapsychiatry.2020.3285
Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R. (2019). 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American Journal of Drug and Alcohol Abuse, 45(2), 161–169. https://doi.org/10.1080/00952990.2018.1545024 Diniz, O. (1999). Usos, bioquímica e atividade biológica do psilocybe SSP [Monografia, Universidade do Estado do Rio de Janeiro - UERJ].
Doblin, R. (2015). From the desk of Rick Doblin, Ph.D. - Summer 2015. Multidisciplinary Association for Psychedelic Studies (MAPS). https://maps.org/news/bulletin/articles/5833-bulletin-summer-2015/5872-from-the-desk-of-rick-doblin-summer-2015
Edmundo, P. (2020). Usos terapêuticos da psilocibina. In F. Beserra & S. Rodrigues, Psicodélicos no Brasil: Ciência e Saúde (p. 49–68). Editora CRV.
Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart-Harris, R. L. (2018). Effects of psilocybin therapy on personality structure. Acta Psychiatrica Scandinavica, 138(5), 368–378. https://doi.org/10.1111/acps.12904
Escobar, J. A. C., & Roazzi, A. (2010). Substâncias psicodélicas e psilocibina. Núcleo de Estudos Interdisciplinares sobre Psicoativos-NEIP. Disponível em: https://neip.info/novo/wp-content/uploads/2015/04/escobarroazzi_substncias.pdf
Fanhofmann, M. (2019). Ayahuasca e psilocibina - Ensaios sobre ciência, legislação, sociedade, espiritualidade e terapias psicodélicas (2. ed.). Clube dos Autores.
Garcia-Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., & Johnson, M. W. (2020). Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Frontiers in Psychiatry, 10(955). https://doi.org/10.3389/fpsyt.2019.00955
Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology (Oxford, England), 33(9), 1088–1101. https://doi.org/10.1177/0269881119845793
Goodwin, G. M., Malievskaia, E., Fonzo, G. A., & Nemeroff, C. B. (2023). Must psilocybin always “assist psychotherapy”? American Journal of Psychiatry, 181(1), 1–82. https://doi.org/10.1176/appi.ajp.20221043
Gosling, S. D., Vazire, S., Srivastava, S., & John, O. P. (2004). Should we trust web-based studies? A comparative analysis of six preconceptions about internet questionnaires. American Psychologist, 59(2), 93–104. https://doi.org/10.1037/0003-066X.59.2.93
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology (Oxford, England), 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–283. https://doi.org/10.1007/s00213-006-0457-5
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology (Oxford, England), 28(11), 983–992. https://doi.org/10.1177/0269881114548296
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017a). Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse, 43(1), 55–60. https://doi.org/10.3109/00952990.2016.1170135
Johnson, M. W., Garcia-Romeu, A., Johnson, P. S., & Griffiths, R. R. (2017b). An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology (Oxford, England), 31(7), 841–850. https://doi.org/10.1177/0269881116684335
Kaertner, L. S., Steinborn, M. B., Kettner, H., Spriggs, M. J., Roseman, L., Buchborn, T., Balaet, M., Timmermann, C., Erritzoe, D., & Carhart-Harris, R. L. (2021). Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Scientific Reports, 11(1941). https://doi.org/10.1038/s41598-021-81446-7
Kohlsdorf, M., & Costa, Á. L., Jr. (2009). O autorrelato na pesquisa em psicologia da saúde: Desafios metodológicos. Psicol. Argum., 27(57), 131–139. http://repositorio.unb.br/handle/10482/6028
Krebs, T. S., & Johansen, P. (2013). Over 30 million psychedelic users in the United States. F1000Research, 2(98). https://doi.org/10.12688/f1000research.2-98.v1
Lipp, M. E. N., & Lipp, L. M. N. (2020). Stress e transtornos mentais durante a pandemia da COVID-19 no Brasil. Boletim - Academia Paulista de Psicologia, 40(99), 180–191. http://pepsic.bvsalud.org/scielo.php?script=sci_arttext&pid=S1415-711X2020000200003&lng=pt&tlng=pt.
Lipp, M. E. N., & Lipp, L. M. N. (2022). O impacto da pandemia da covid-19 no nível de stress, saúde mental e valores do ser humano. Boletim - Academia Paulista de Psicologia, 42(103), 124–132. https://doi.org/10.5935/2176-3038.20220013
Lipp, M. E. N., Sagradim, D. E. V., Saar, M., Araújo, S. R., & Lipp, L. M. N. (2023). Stress no Brasil 2022: A herança da pandemia da covid-19. Boletim - Academia Paulista de Psicologia, 43(104), 26–37. https://doi.org/10.5935/2176-3038.20230004
Lovibond, S. H., & Lovibond, P. F. (2004). Manual for the Depression Anxiety Stress Scales (4o ed). Psychology Foundation.
Ministério da Saúde. (1998). Portaria no 344, de 12 de maio de 1998. Aprova o Regulamento Técnico sobre substâncias e medicamentos sujeitos a controle especial. Diário Oficial da União. https://bvsms.saude.gov.br/bvs/saudelegis/svs/1998/prt0344_12_05_1998_rep.html
Morais, P. R., Areco, N. K. C., Fidalgo, T. M., & Silveira, D. X. (2022). Mental health and quality of life in a population of recreative cannabis users in Brazil. Journal of Psychiatric Research, 146, 11–20. https://doi.org/10.1016/j.jpsychires.2021.12.010
Nichols, D. E. (2014). The Heffter Research Institute: Past and hopeful future. Journal of Psychoactive Drugs, 46(1), 20–26. https://doi.org/10.1080/02791072.2014.873688
Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478
Orsolini, L., Papanti, G. D., Francesconi, G., & Schifano, F. (2015). Mind navigators of chemicals’ experimenters? A web-based description of e-psychonauts. Cyberpsychology, Behavior and Social Networking, 18(5), 296–300. https://doi.org/10.1089/cyber.2014.0486
Orsolini, L., John-Smith, P., St., McQueen, D., Papanti, D., Corkery, J., & Schifano, F. (2017). Evolutionary considerations on the emerging subculture of the e-psychonauts and the novel psychoactive substances: A comeback to the shamanism? Current Neuropharmacology, 15(5), 731–737. https://doi.org/10.2174/1570159X15666161111114838
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002). The pharmacology of psilocybin. Addiction Biology, 7(4), 357–364. https://doi.org/10.1080/1355621021000005937
Perkins, D., Schubert, V., Simonová, H., Tófoli, L. F., Bouso, J. C., Horák, M., Galvão-Coelho, N. L., & Sarris, J. (2021). Influence of context and setting on the mental health and wellbeing outcomes of ayahuasca drinkers: Results of a large international survey. Frontiers in Pharmacology, 12(623979). https://doi.org/10.3389/fphar.2021.623979
Phelps, J. (2017). Developing guidelines and competencies for the training of psychedelic therapists. Journal of Humanistic Psychology, 57(5), 450–487. https://doi.org/10.1177/0022167817711304
Ramos, F. P., Reis, L. B., Iglesias, A., Andrade, A. L. D., Gandra, C. T., & Costa, E. F. (2024). Consumo de drogas como estratégia de regulação emocional durante pandemia de COVID-19. Revista Psicologia em Pesquisa, 18(3). https://doi.org/10.34019/1982-1247.2024.v18.36131
Roberts, C. A., Osborne-Miller, I., Cole, J., Gage, S. H., & Christiansen, P. (2020). Perceived harm, motivations for use and subjective experiences of recreational psychedelic “magic” mushroom use. Journal of Psychopharmacology (Oxford, England), 34(9), 999–1007. https://doi.org/10.1177/0269881120936508
Rootman, J. M., Kryskow, P., Harvey, K., Stamets, P., Santos-Brault, E., Kuypers, K. P. C., Polito, V., Bourzat, F., & Walsh, Z. (2021). Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Scientific Reports, 11(22479). https://doi.org/10.1038/s41598-021-01811-4
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology, 8(974). https://doi.org/10.3389/fphar.2017.00974
Rosenbaum, D., Weissman, C., Anderson, T., Petranker, R., Dinh-Williams, L., Hui, K., & Hapke, E. (2020). Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities. Journal of Psychopharmacology (Oxford, England), 34(6), 612–622. https://doi.org/10.1177/0269881120908004
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology (Oxford, England), 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512
Salvador, P. T. C. O., Alves, K. Y. A., Rodrigues, C. C. F. M., & Oliveira, L. V. (2020). Estratégias de coleta de dados online nas pesquisas qualitativas da área da saúde: Scoping review. Revista Gaúcha de Enfermagem, 41(e20190297). https://doi.org/10.1590/1983-1447.2020.20190297
Schenberg, E. E. (2018). Psychedelic-Assisted Psychotherapy: A paradigm shift in psychiatric research and development. Frontiers in Pharmacology, 9(733). https://doi.org/10.3389/fphar.2018.00733
Schultes, R. E. (1969). Hallucinogens of plant origin: Interdisciplinary studies of plants sacred in primitive cultures yield results of academic and practical interest. Science (New York, N.Y.), 163(3864), 245–254. https://doi.org/10.1126/science.163.3864.245
Sellers, E. M. (2017). Psilocybin: Good trip or bad trip. Clinical Pharmacology and Therapeutics, 102(4), 580–584. https://doi.org/10.1002/cpt.697
Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bossong, M. G., & Batalla, A. (2023). Therapeutic effect of psilocybin in addiction: A systematic review. Frontiers in Psychiatry, 14(1134454). https://doi.org/10.3389/fpsyt.2023.1134454
Vignola, R. C. B. (2013). Escala de depressão, ansiedade e estresse (DASS): Adaptação e validação para o português do Brasil [Dissertação de Mestrado, Universidade Federal de São Paulo]. https://repositorio.unifesp.br/handle/11600/48328
Vignola, R. C. B., & Tucci, A. M. (2014). Adaptation and validation of the depression, anxiety and stress scale (DASS) to Brazilian Portuguese. Journal of Affective Disorders, 155, 104–109. https://doi.org/10.1016/j.jad.2013.10.031
Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. Journal of Humanistic Psychology, 57(5) 520–564. https://doi.org/10.1177/0022167817709585
Winstock, A. R., Timmerman, C., Davies, E., Maier, L. J., Zhuparris, A., Ferris, J. A., Barratt, M. J., & Kuypers, K. P. C. (2021). GDS 2020 Psychedelics Key Finding Report. Global Drug Survey (GDS).
